Pharmaceutical - Amylin


Current filters:


Popular Filters

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed


Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were…

AmylinAstraZenecaBristol-Myers SquibbDiabetesInterviewsLegalMergers & AcquisitionsPharmaceuticalUKUSA

Briefs: Pfizer $142 million fine upheld; Bristol-Myers shuts Amylin facility


The US Court of Appeals in Boston has upheld a $142.1 million damage award to Kaiser Foundation Health…

AmylinBristol-Myers SquibbLegalManagementMarkets & MarketingNeurontinNorth AmericaPfizerPharmaceutical

Head-to-head trial of diabetes drugs Victoza and Bydureon yields mixed results


A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded…

AmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

Investor Icahn slams Amylin for not revealing B-MS bid


Billionaire US investor Carl Icahn has sent a blistering open letter to the board of US biotech company…

AmylinBiotechnologyBristol-Myers SquibbMergers & AcquisitionsPharmaceutical

Byetta cleared for add-on therapy with basal insulin in EU


US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN) and drug major Eli Lilly (NYSE: LLY) said on Friday…

AmylinByettaDiabetesEli LillyEuropePharmaceuticalRegulation

FDA finally approves Bydureon


There was good news on Friday for USA-based Amylin Pharmaceuticals (Nasdaq: AMLN) and Alkermes (Nasdaq:…

AlkermesAmylinBydureonDiabetesEli LillyNorth AmericaPharmaceuticalRegulation

Back to top